翰宇药业(300199) - 2025 Q1 - 季度财报

Revenue and Profitability - The company's revenue for Q1 2025 reached ¥309,969,965.34, representing a 106.29% increase compared to ¥150,256,744.79 in the same period last year[5] - Net profit attributable to shareholders was ¥69,868,367.53, a significant turnaround from a loss of ¥14,102,003.37, marking a 595.45% increase[5] - Basic and diluted earnings per share improved to ¥0.08, compared to a loss of ¥0.02 per share in the same period last year, reflecting a 500.00% increase[5] - The net profit for the current period was ¥69,439,025.34, a turnaround from a net loss of ¥14,350,051.02 in the previous period[22] - The profit attributable to the parent company's shareholders was ¥69,868,367.53, compared to a loss of ¥14,102,003.37 in the prior period[23] - The company reported a total comprehensive income of ¥69,339,641.98, recovering from a loss of ¥14,111,841.40 in the previous period[23] Cash Flow - The net cash flow from operating activities was ¥40,425,295.32, up 166.79% from ¥15,152,592.91 in the previous year[5] - Cash flow from operating activities showed a significant improvement, with cash received from sales reaching ¥190,318,882.35, compared to ¥130,536,094.26 in the previous period[25] - The net cash flow from operating activities was $40,425,295.32, an increase from $15,152,592.91 in the previous period, indicating a significant improvement in operational efficiency[26] - Total cash inflow from financing activities was $70,000,000.00, while cash outflow amounted to $120,077,959.58, resulting in a net cash flow of -$50,077,959.58, reflecting a decrease in financing activities[26] - The total cash inflow from investment activities was $3,746,209.90, while cash outflow was $34,282,205.58, leading to a net cash flow of -$30,535,995.68, indicating a substantial investment in assets[26] - The company received $9,311,755.88 in tax refunds, contributing positively to cash inflows from operating activities[26] Assets and Liabilities - The total assets at the end of Q1 2025 were ¥3,038,045,570.70, a slight increase of 0.99% from ¥3,008,225,640.09 at the end of the previous year[5] - Total current assets amount to ¥494,618,808.48, an increase from ¥463,048,006.84 at the beginning of the period[18] - Total liabilities decreased slightly to ¥2,371,659,416.70 from ¥2,411,179,128.07, reflecting a reduction of approximately 1.6%[22] - The company has a total of ¥82,878,785.91 in contract liabilities, down from ¥124,478,071.04, indicating a reduction of approximately 33%[18] Shareholder Information - Total number of common shareholders at the end of the reporting period is 57,273[14] - The largest shareholder, Zeng Shaogui, holds 11.16% of shares, amounting to 98,533,635 shares, with 95,732,245 shares pledged[14] - The company is actively involved in financing activities, with a notable shareholder, Tibet Rongrui Investment Co., holding 5,286,600 shares through margin trading[15] Operating Costs and Expenses - The company's operating costs increased by 115.64% to ¥128,088,503.11, mainly due to higher formulation costs[10] - Total operating costs amounted to ¥231,507,233.07, compared to ¥156,147,173.76 in the prior period, indicating an increase of about 48.2%[22] - Cash paid to employees increased to ¥58,222,746.22 from ¥35,535,450.97, reflecting a rise in labor costs[26] Research and Development - The company has ongoing research and development efforts, with development expenditures amounting to ¥142,685,817.52, up from ¥136,673,090.93[18] - Research and development expenses rose to ¥21,707,434.32 from ¥18,999,351.04, an increase of approximately 9.0%[22] Inventory and Accounts Receivable - The increase in accounts receivable was 73.91%, reaching ¥166,562,869.28, primarily due to increased revenue[9] - Accounts receivable increased significantly to ¥166,562,869.28 from ¥95,773,533.23, indicating a growth of approximately 74%[18] - Inventory decreased to ¥225,749,209.48 from ¥238,630,347.88, reflecting a decline of about 5.4%[18] Audit and Reliability - The company did not undergo an audit for the first quarter report, which may affect the reliability of the financial data presented[28]